Can Probiotics Help In Managing Or Preventing Fatty Liver Disease?
Quick answer
Probiotics may help improve liver enzyme levels, hepatic steatosis, and some metabolic parameters in patients with non-alcoholic fatty liver disease (NAFLD), but evidence varies by strain and study design.
🔬 What the research shows
Multiple high-quality randomized controlled trials and meta-analyses indicate that probiotics and synbiotics can reduce liver enzymes (ALT, AST, GGT), improve hepatic steatosis as assessed by imaging, and positively affect lipid and glucose metabolism in NAFLD patients. Synbiotic yogurt containing Bifidobacterium animalis showed significant improvements in liver steatosis and enzymes over 24 weeks. Meta-analyses of over 1000 patients confirm probiotics improve liver function, steatosis, blood lipids, and insulin resistance, especially with treatment durations of 12 weeks or longer. However, one RCT using a multi-strain probiotic (MCP BCMC strains) did not find significant clinical improvements in hepatic steatosis or fibrosis but suggested probiotics may stabilize intestinal mucosal immunity and barrier function. Another clinical trial protocol plans to evaluate Lactobacillus acidophilus and Bifidobacterium lactis strains but results are pending. Preclinical and mechanistic studies highlight the role of gut microbiota modulation, including strains like Akkermansia muciniphila, in NAFLD pathogenesis and potential treatment. Overall, probiotics appear promising as adjunctive therapy for NAFLD, but strain-specific effects, optimal formulations, and long-term benefits require further research.
Best studied probiotic strains
Bifidobacterium animalis
A 24-week RCT showed that synbiotic yogurt containing Bifidobacterium animalis significantly decreased liver steatosis grades and improved liver enzymes (ALT, AST, GGT) compared to conventional yogurt and control groups (PMID: 29931231).
Evidence is from a high-quality RCT with a relatively large sample size; effects observed with synbiotic yogurt including prebiotic inulin.
Lactobacillus acidophilus and Bifidobacterium lactis
A clinical trial protocol plans to assess effects of probiotic yogurt containing these strains on liver enzymes, steatosis, and fibrosis in NAFLD patients (PMID: 35255811). Results are pending.
Evidence is currently moderate and based on planned study; no published results yet.
MCP BCMC multi-strain probiotics
A 6-month RCT using a multi-strain probiotic containing six unspecified strains showed no significant clinical improvement in hepatic steatosis or fibrosis but suggested stabilization of intestinal mucosal immune function (PMID: 34579068).
Strain details are not fully specified; clinical benefits were not significant but some immunological effects noted.
Akkermansia muciniphila
Preclinical and observational studies suggest that decreased abundance of Akkermansia muciniphila is associated with NAFLD and that increasing its levels may improve metabolic parameters (PMID: 24966608).
Evidence is low and mostly preclinical; no direct clinical trials in NAFLD patients.
👥 Who may benefit
✅ Safety
Probiotics and synbiotics used in the reviewed studies were generally well tolerated with no significant adverse effects reported. However, safety data are limited and long-term effects require further study.
⚠️ Limitations
Heterogeneity exists in probiotic strains, dosages, treatment durations, and study designs. Some studies have small sample sizes or lack strain specificity. Clinical improvements in liver fibrosis and inflammation are less consistently demonstrated. More large-scale, well-designed RCTs with defined probiotic strains and longer follow-up are needed to confirm efficacy and optimal protocols.